
Ventus Therapeutics Doses First Patient in Phase 2a Trial of VENT-02 for Parkinson’s Disease
Ventus Therapeutics Doses First Patient in Phase 2a Trial of VENT-02 for Parkinson’s Disease Ventus Therapeutics, a clinical-stage biopharmaceutical company, has announced that the first patient has been dosed in its Phase 2a clinical trial evaluating VENT-02 in patients with…












